These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 26776081)

  • 1. Position Emission Tomography/Single-Photon Emission Tomography Neuroimaging for Detection of Premotor Parkinson's Disease.
    Zou J; Weng RH; Chen ZY; Wei XB; Wang R; Chen D; Xia Y; Wang Q
    CNS Neurosci Ther; 2016 Mar; 22(3):167-77. PubMed ID: 26776081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging the Nonmotor Symptoms in Parkinson's Disease.
    Yousaf T; Wilson H; Politis M
    Int Rev Neurobiol; 2017; 133():179-257. PubMed ID: 28802921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease.
    Booij J; Knol RJ
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S425-8. PubMed ID: 18267276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging in Parkinson's disease: the role of monoamines in behavior.
    Brooks DJ; Piccini P
    Biol Psychiatry; 2006 May; 59(10):908-18. PubMed ID: 16581032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging.
    Berendse HW; Ponsen MM
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S26-30. PubMed ID: 20083001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging non-dopaminergic function in Parkinson's disease.
    Brooks DJ
    Mol Imaging Biol; 2007; 9(4):217-22. PubMed ID: 17340229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroimaging of nonmotor features of Parkinson's disease.
    Deblieck C; Wu AD
    Rev Neurol Dis; 2008; 5(3):125-33. PubMed ID: 18838952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing diagnosis in Parkinson's disease: Radionuclide imaging.
    Arena JE; Stoessl AJ
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S47-51. PubMed ID: 26439947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research progress in the early diagnosis of Parkinson's disease.
    Xie L; Hu L
    Neurol Sci; 2022 Nov; 43(11):6225-6231. PubMed ID: 35948779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging beyond the striatonigral dopaminergic system in Parkinson's disease.
    Giza E; Gotzamani-Psarrakou A; Bostantjopoulou S
    Hell J Nucl Med; 2012; 15(3):224-32. PubMed ID: 23106055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography in premotor Parkinson's disease.
    Stoessl AJ
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S421-4. PubMed ID: 18267275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional imaging in pre-motor Parkinson's disease.
    Arnaldi D; Morbelli S; Picco A; Ferrara M; Buschiazzo A; Famà F; De Carli F; Nobili F
    Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):366-75. PubMed ID: 25366709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers in Parkinson's disease (recent update).
    Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
    Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease.
    de Natale ER; Niccolini F; Wilson H; Politis M
    Int Rev Neurobiol; 2018; 141():131-172. PubMed ID: 30314595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography in diagnosis and differential diagnosis of Parkinson's disease.
    Tatsch K
    Neurodegener Dis; 2010; 7(5):330-40. PubMed ID: 20616567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotracers for imaging of Parkinson's disease.
    Abbasi Gharibkandi N; Hosseinimehr SJ
    Eur J Med Chem; 2019 Mar; 166():75-89. PubMed ID: 30685535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in 5-HT2A receptor expression in untreated, de novo patients with Parkinson's disease.
    Melse M; Tan SK; Temel Y; van Kroonenburgh MJ; Leentjens AF
    J Parkinsons Dis; 2014; 4(2):283-7. PubMed ID: 24398658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single photon-emission computed tomography imaging in early Parkinson's disease.
    Antonini A; Isaias IU
    Expert Rev Neurother; 2008 Dec; 8(12):1853-64. PubMed ID: 19086881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.